ClinicalTrials.gg
RecruitingNCT07857460HyPaRegUpdated Oct 5, 2026

German Hypoparathyroidism Registry

An observational study in Hypoparathyroidism and Pseudohypoparathyroidism, sponsored by University Hospital Augsburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University Hospital Augsburg · Observational

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.
Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

Chronic hypoparathyroidism is a rare condition in which the parathyroid glands do not make enough parathyroid hormone (PTH). PTH helps control the levels of calcium and phosphate in the blood. When there is not enough PTH, calcium levels can become too low and phosphate levels can become too high. This may cause symptoms such as tingling, muscle cramps, weakness, or other health problems.

The most common cause of chronic hypoparathyroidism is surgery in the neck area. It can happen after thyroid surgery, surgery on the parathyroid glands, or other operations in the neck.

At the moment, most patients are treated with calcium and vitamin D tablets. These treatments help control calcium levels, but they cannot fully replace the normal effects of PTH in the body. A medicine that contains a form of human PTH is available for some patients, but it is not yet the standard treatment for everyone.

This registry collects medical information and follows patients over time. Its aim is to better understand patients' symptoms, possible long-term health problems, treatments, and overall health. A group of patients who have had their thyroid removed but do not have hypoparathyroidism will also be included for comparison.

Read the detailed description

Chronic hypoparathyroidism is a rare endocrine disorder characterized by persistently reduced or absent secretion of parathyroid hormone (PTH), resulting in hypocalcemia and hyperphosphatemia with a broad spectrum of associated clinical manifestations. The most common etiology is postsurgical hypoparathyroidism, particularly following thyroid surgery, but it may also occur after parathyroid surgery or other surgical procedures involving the neck.

Hypoparathyroidism remains unique among endocrine deficiency disorders in that replacement of the deficient hormone has not yet become established as standard therapy. Although recombinant human PTH-based therapies are available for selected patient populations, conventional treatment currently relies primarily on oral calcium and vitamin D supplementation. While this approach can improve biochemical control, it does not fully reproduce the physiological actions of endogenous PTH and may therefore be associated with limitations in both short- and long-term disease management.

In Germany, systematic longitudinal data on patients with chronic hypoparathyroidism is limited. Therefore, this is a local registry for the structured documentation and follow-up of patients with chronic hypoparathyroidism and pseudohypoparathyroidism. The registry is intended to provide a structured basis for clinical, translational and basic research on chronic hypoparathyroidism. Key areas of investigation include the frequency, and severity of disease-related symptoms, diagnostic approaches and biochemical monitoring, organ specific effects, the effectiveness and limitations of conventional therapy and the emerging and novel therapeutic strategies, including PTH replacement therapies. Particular attention will also be given to long-term complications and associated comorbidities, treatment-related outcomes, quality of life and special life events like pregnancies.

Longitudinal follow-up will allow the clinical course of the disease, treatment requirements, and long-term outcomes to be assessed systematically. In addition, a cohort of patients who have undergone thyroidectomy without subsequent hypoparathyroidism will serve as a control group, allowing outcomes associated specifically with chronic hypoparathyroidism to be distinguished from those related to thyroid surgery and its underlying indications.

02

Conditions studied

  • Hypoparathyroidism
  • Pseudohypoparathyroidism

Keywords

  • registry
  • hypoparathyroidism
  • pseudohypoparathyroidism
03

In context

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

This study's planned enrollment of 150 is close to the median of 147 across 48 observational studies indexed under Hypoparathyroidism.

Browse Hypoparathyroidism studies →

Lead sponsor

University Hospital Augsburg is the lead sponsor of 25 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients within the area of Augsburg and southern Germany

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of chronic hypo- or pseudohypoparathyroidism > 6 months or diagnosis of pseudohypoparathyroidism
  • age >= 18 yrs.
  • residing in Germany
  • Written consent for patients capable of giving

Exclusion criteria

Exclusion Criteria:

  • Minors and patients with severe mental illnesses, or patients who are unable to provide written .

Controll group

  • h/o thyroidektomy with thyroid hormone replacement
  • age >= 18 yrs.
  • residing in Germany
  • The exclusion criteria also apply to this group.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. long-term comorbidities in hypoparathyroidism

    compared with a controll group

    Time frame: 15 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Siggelkow H, Peschke KA, Tsourdi E, Hofbauer LC, Berr CM, Hahner S, Lottspeich C, Schmidmaier R, Blaschke M. Switch From rhPTH1-84 to TransCon PTH With Individual Dose Adjustment in Adult Hypoparathyroidism-4-Week Results. J Endocr Soc. 2025 Jun 30;9(9):bvaf113. doi: 10.1210/jendso/bvaf113. eCollection 2025 Sep. PubMed 40709359 ↗
  • Berr CM, Fuss CT, Gronemeyer K, Lohr B, Pfob CH, Pusl T, Hahner S. Morning urinary calcium/creatinine ratio as a sex-specific screening tool for detecting hypercalciuria in hypoparathyroidism. Eur J Intern Med. 2026 Jun;148:106740. doi: 10.1016/j.ejim.2026.106740. Epub 2026 Feb 28. PubMed 41763924 ↗

Individual participant data

Plan to share: Undecided — The data is available on reasonable request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Feb 2036, 174 months after the start.

Of 25 observational studies under Hypoparathyroidism, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 122. This study's planned 174 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 5, 2026
StartActual
Jul 6, 2021
Primary completionEst.
Feb 1, 2036
CompletionEst.
Dec 31, 2037
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857460
Lead sponsor
University Hospital Augsburg
Collaborators
Wuerzburg University Hospital, Ascendis Pharma Endocrinology Division A/S
Responsible party
Christina Berr. MD (Specialist in endocrinology, University Hospital Augsburg) — Principal investigator
First posted
Oct 5, 2026
Start date
Jul 6, 2021
Primary completion
Feb 1, 2036 (estimated)
Completion
Dec 31, 2037 (estimated)
Last update
Oct 5, 2026

Study contacts

Christina M. Berr, Dr.
Contact
endokrinologie@uk-augsburg.de
+498214003938
Thomas Pusl, PD Dr.
Contact
+498214002355

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion